Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 6, 2014, Pages 835-844

  Eller, Thomas ^a   Busse, Jessica ^b   Dittrich, Marcus ^c   Flieder, Tobias ^b   Alban, Susanne ^d   Knabbe, Cornelius ^b   Birschmann, Ingvild ^b  

^a KLINIKUM MINDEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

Direct oral anticoagulants; Direct thrombin inhibitors; Platelets; Point of care systems; Preanalytics

Indexed keywords

APIXABAN; ARGATROBAN; DABIGATRAN; FONDAPARINUX; RIVAROXABAN; THROMBIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PIPECOLIC ACID DERIVATIVE; POLYSACCHARIDE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TIME; BLOOD SAMPLING; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; POINT OF CARE TESTING; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; THROMBOELASTOGRAPH; ANALOGS AND DERIVATIVES; ARTIFACT; BLOOD CLOTTING; DRUG EFFECTS; HOSPITAL INFORMATION SYSTEM; PROCEDURES; THROMBOELASTOGRAPHY;

ANTICOAGULANTS; ARTIFACTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; HUMANS; MORPHOLINES; PIPECOLIC ACIDS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; POLYSACCHARIDES; PYRAZOLES; PYRIDONES; THIOPHENES; THROMBELASTOGRAPHY; WHOLE BLOOD COAGULATION TIME;

EID: 84903596893     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0936     Document Type: Article

References (30)

1. Saito H, Matsushita T, Kojima T. Historical perspective and future direction of coagulation research. J Thromb Haemost 2011;9(Suppl 1):352-63
2. Soff GA. A new generation of oral direct anticoagulants. Arterioscler Thromb Vasc Biol 2012;32:569-74
3. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):204S-33S (Pubitemid 39297955)
4. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th e. American College of Chest Physicians evidencebased clinical practice guidelines. Chest 2012;141(2 Suppl):7S-47S
5. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981;101:440-6
6. Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 2001;58(Suppl 2):S14-7 (Pubitemid 33027571)
7. Pradaxa (dabigatran) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2012
8. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008;47:203-16
9. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81
10. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007;5:2368-75 (Pubitemid 350154345)
11. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost 2013;11:756-60
12. Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 2013;59:807-14
13. Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol 2013;35:262-8
14. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013;11:1493-502
15. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-9
16. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8
17. Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009;20:7-11
18. Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 2010;104:302-10
19. Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. J Pharm Biomed Anal 2012;58:152-6
20. Alban S, Luhn S, Schiemann S. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins. Anal Bioanal Chem 2011;399:681-90
21. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995;21(Suppl 2):106-12
22. Michal F, Born GV. Effect of the rapid shape change of platelets on the transmission and scattering of light through plasma. Nat New Biol 1971;231:220-2
23. Adcock DM, Gosselin R, Kitchen S, Dwyre DM. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 2013;139:102-9
24. Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013;29(7 Suppl): S24-33
25. Neyens R, Bohm N, Cearley M, Andrews C, Chalela J. Dabigatranassociated subdural hemorrhage: using thromboelastography (TEG) to guide decision-making. J Thromb Thrombolysis 2013 May 11. [Epub ahead of print]
26. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985-97
27. Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002;107:241-4 (Pubitemid 35435383)
28. Xu Y, Wu W, Wang L, Chintala M, Plump AS, Ogletree ML, et al. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis 2013;24:332-8
29. Engstrom M, Rundgren M, Schott U. An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time. Acta Anaesthesiol Scand 2010;54:86-91
30. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30:270-382.